Biopharma R&D, from drug discovery through to late phase clinical trials, suffers from two fundamental, near industry-threatening problems: it is too slow and too expensive.

With payers and the public getting increasingly vocal about drug prices, the long-standing tactic of passing on costs to the healthcare system is precarious.

Download to find out more.